Patent ID: 11903971
Assignee: CELLPHIRE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of treating von Willebrand disease in a subject, the method comprising:
administering a therapeutically effective amount of freeze-dried platelet derivatives intravenously to the subject in need thereof, wherein the plasma of the subject is deficient in von Willebrand factor, and the therapeutically effective amount of freeze-dried platelet derivatives is an amount sufficient to form clots in plasma of the subject, wherein the therapeutically effective amount of freeze-dried platelet derivatives is at least 8.5×108 particles/kg of the subject, and wherein the surface expression of CD42b on the freeze-dried platelet derivatives is between 25% and 50% of the surface expression of CD42b on normal platelets, and wherein the freeze-dried platelet derivatives are loaded with an anti-fibrinolytic agent selected from ε-aminocaproic acid, aprotinin, aminomethylbenzoic acid, tranexamic acid, and fibrinogen.